Multi-cancer Blood Tests: What Will It Take to Make Them Routine?
Published on 27 Oct, 2026
Multi-cancer blood tests will become routine only when four things happen in order: evidence that moves from detecting cancer to improving treatment outcomes, a payment pathway that turns a self-pay test into a covered benefit, health-system capacity to absorb every positive result, and guidance that tells clinicians whom to test and what to do next.
On September 23, 2026, an FDA advisory panel backed GRAIL's Galleri test, voting 7 to 2, with one abstention that benefits the outweigh risks. This vote advances the regulatory and payment steps. It does not complete the evidence step, and the other two have barely started.
The short answer
Most coverage of the panel vote asks whether Galleri will be approved. The more useful question is what must be true for a screening test to move from something a patient buys to something a health system routinely offers. Our reading is that the path runs through four gates, and that they open in sequence rather than together.
The first gate, evidence, is the hardest and the least settled. The second, payment, has moved the furthest: a US law signed in February 2026 creates a Medicare route for approved tests. The third, follow-up capacity, and the fourth, clinical guidance, depend on the first two and have not been addressed in detail. The most likely route to routine use is, therefore, narrow before it is broad: a defined group of older adults, cancers for which no guideline-recommended screening test currently exists, and Medicare as the first payer.
Where the evidence stands
The panel voted 10 to 0 on safety, 6 to 4 on effectiveness, and 7 to 2, with one abstention on benefit-risk, according to Targeted Oncology and CancerNetwork. The proposed indication is screening adults aged 50 and older for multiple cancer types. The proposed label says Galleri does not replace recommended screening and that a positive result needs confirmatory diagnosis. It is not an approval, and the FDA decision is expected in the coming months.
Two studies published on September 22, 2026 explain the split. PATHFINDER 2 (Nabavizadeh et al., Nature Medicine) followed 32,007 participants and reported specificity of 99.64 percent, a positive predictive value of 60.3 percent, and episode sensitivity of 39.3 percent across all cancers. NHS-Galleri (Sasieni et al., New England Journal of Medicine) randomized 142,250 people and did not reduce stage III or IV cancers, the primary endpoint (rate ratio 1.03; 95 percent CI 0.92−1.15). Stage IV incidence was lower (rate ratio 0.86; 95 percent CI 0.74−1.00), and a post hoc analysis showed more early-stage diagnoses, but neither was the primary endpoint.
The findings of both studies differ. The test is precise and finds a meaningful minority of cancers, but it has not yet been shown to shift cancer diagnosis from a late- to an early-stage in a randomized setting. This gap between detection and benefit is the central issue for routine use.
The practical meaning is asymmetric. When Galleri flags a signal, it usually reflects a real cancer, which makes a positive result informative. A negative result offers limited reassurance, which is why the label warns that it does not rule out cancer. A small false positive rate becomes a large absolute number once a test is offered to millions of people.
What a screening test must demonstrate
Screening is judged differently from treatment, as it is given to healthy people. An early diagnosis must improve treatment outcomes, and the benefit must outweigh the harms of false alarms, unnecessary workup, and overdiagnosis. A test, therefore, climbs a ladder of evidence, and each rung is a precondition for the next.
Exhibit 1: The evidence ladder and where Galleri stands
| Rung | What it shows | Status for Galleri |
|---|---|---|
| Test performance | Detects cancer and avoids false alarms | Largely met, high specificity and positive predictive value; modest sensitivity |
| Safety | Testing and follow-up cause little harm | Met in the panel vote (10 to 0); invasive procedures after a positive result in 0.6% of the safety population |
| Stage shift | Cancers are found earlier and late-stage disease falls | Primary endpoint missed; stage IV and early-stage signals need confirmation |
| Mortality benefit | Fewer people die of cancer | Not shown |
| Net benefit | Benefit outweighs harms and costs at population scale | Not shown |
Source: CancerNetwork, Nabavizadeh et al. (Nature Medicine, 2026), Sasieni et al. (New England Journal of Medicine, 2026), Aranca analysis. The panel also heard that performance figures came from retesting stored plasma samples with the current assay, as Epocrates reported.
The ladder shows why an approval would not end the question. Galleri stands firmly on the first two rungs and unsteadily on the third. Payers and guideline bodies tend to want the upper rungs before they treat a test as routine, so the evidence gate will stay open for some time after any FDA decision.
The four gates in order
- Gate 1: evidence. What is needed is confirmation that the stage IV and later-round signals reflect a true stage shift, followed by evidence on patient outcomes. NHS-Galleri's later rounds trended lower than the first (rate ratios of 0.95 and 0.88 against 1.19), which is consistent with a screening effect that builds over repeated rounds, although it is not proof of one. Longer follow-up is what would settle it.
- Gate 2: payment. Under a law signed on February 3, 2026, Medicare could begin covering FDA-approved multi-cancer tests in 2028, but only once the Centers for Medicare & Medicaid Services (CMS) decides on coverage, and with limits on age and a cap of one test every 11 months, as the Congress.gov summary and AZBio describe. Becker's Payer Issues cites 2029 and payment parity with multi-target stool DNA tests through 2030, so the start date should be confirmed against the enacted text. Currently, the test sells for $949 without insurance coverage, as reported by eMarketer, and private insurers generally follow U.S. Preventive Services Task Force (USPSTF) recommendations.
- Gate 3: follow-up capacity. Every positive result sends a patient into diagnostic workup. PATHFINDER 2 recorded 213 invasive procedures and 114 false positive results, manageable at study scale but growing with volume. By GRAIL's own account, it sold over 185,000 tests in 2025 and more than 117,000 in the first six months of 2026, a sign of how quickly demand can build without insurance coverage.
- Gate 4: guidance. Clinicians need clear direction on who should be tested, how to interpret a negative result, and how to manage a positive signal with no identified tumour. Without it, a covered test will be ordered inconsistently.
Exhibit 2: The gates, who holds each key, and where things stand
| Gate | Who holds the key | Current status | What opens it |
|---|---|---|---|
| Evidence | FDA, guideline bodies, researchers | Primary endpoint missed; secondary signals | Confirmed stage shift and outcome data |
| Payment | Congress, CMS, USPSTF, private payers | Medicare pathway enacted; start 2028 or 2029 by source | FDA approval, then a CMS coverage determination |
| Follow-up capacity | Health systems, diagnostic providers | Low invasive-procedure rate at study scale | Standard workup pathways and imaging capacity |
| Guidance | Professional societies, USPSTF | Add-on label; already ordered as a laboratory-developed test | Recommendations on who to test and how to act on results |
Source: Congress.gov; AZBio; Becker's Payer Issues; eMarketer; Epocrates; CancerNetwork; Aranca analysis.
A likely path to routine use
Putting the gates in sequence suggests a staged route. This is a reasoned sequence, not a forecast, and each step could slip.
- Stage one: the FDA decision. Galleri remains a self-pay and an add-on test. The decision on the label matters, as it sets what can be claimed and opens the Medicare route.
- Stage two: a narrow-covered use. If the FDA approves and CMS follows, coverage will probably start for older adults under Medicare, with limits on age and frequency, and with the most credible case for cancers for which no guideline-recommended screening test currently exists. The FDA estimates that 58 percent of 2026 US cancer deaths are caused by cancers without recommended screening, as eMarketer reports, which is where the alternative to testing is no testing at all.
- Stage three: guidelines. Inclusion in recommendations will depend on outcome evidence and not on coverage. This is the step that moves a test from covered to routine.
- Stage four: private payers and employers. These buyers tend to follow guidelines and Medicare precedent, so broad commercial coverage is likely to come last.
Two things could speed this up: confirmed stage IV or mortality evidence, and a lower cost of follow-up per positive result. Two factors could stall it: longer follow-up that fails to confirm the later-round trend, and a false positive burden that health systems find unmanageable.
Why economics set the pace
The economics are misaligned. A test provider is paid per test, while the cost of every false alarm, including imaging and biopsy, falls on health systems and payers. Coverage decisions will, therefore, depend less on the test price than on who absorbs the follow-up cost and whether a stage shift eventually offsets it.
This is also why the narrow route is the sensible one. Where no screening exists, a test with modest sensitivity still adds something. Where cheaper, validated tests exist, it adds cost and false alarms to a process that already works, which is why the label positions Galleri as an add-on and not a replacement.
Our take: Routine use will be earned in steps
Multi-cancer testing will become routine when its benefit is proven, its follow-up is affordable, and clinicians know how to use it. An FDA approval would be an access milestone that opens the Medicare route. It would not be proof of benefit, and it would not make the test routine by itself.
The practical conclusion is that the pace will be set by the slowest gate, which is evidence. Developers should design trials for the endpoints that guideline bodies and payers will accept, and health systems should plan positive-result pathways well before coverage arrives.
What does this mean for stakeholders
- Test developers. Performance data no longer carries a screening claim. Plan for stage shift, outcome endpoints, and labels that match the evidence.
- Payers and employers. Medicare's pathway will generate public cost and benefit data. Waiting for it is a reasonable position, and early coverage carries an evidence risk.
- Health systems. The bottleneck is the positive-result pathway and not the blood draw. Capacity for imaging, referral, and counseling will determine whether false alarms become a burden.
- Investors. Separate regulatory milestones from commercial inflection. Approval is necessary for sustained coverage but is not sufficient.
A measured look ahead
The markers to watch out for are the FDA's decision and label wording, any CMS coverage determination, longer follow-up from NHS-Galleri, and the response of USPSTF and professional societies. The test is ready for a regulatory decision. Routine care will depend on the evidence, payment pathway, and follow-up system maturing together.
